Investigating IL-37's role in controlling inflammation in autoimmune diseases of the central nervous system.
IL-37: a novel regulator of inflammation in CNS autoimmunity
This study is looking at how a new protein called IL-37 can help reduce inflammation in people with multiple sclerosis (MS), by checking how it works in immune cells from MS patients compared to healthy people, which could lead to better treatments for the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11045631 on NIH RePORTER |
What this research studies
This research focuses on understanding how IL-37, a newly identified cytokine, can regulate inflammation in conditions like multiple sclerosis (MS). The study aims to explore the expression of IL-37 receptors in immune cells from MS patients and how IL-37 can potentially block harmful inflammation. By using advanced laboratory techniques, researchers will compare immune responses in MS patients to healthy individuals and assess the therapeutic effects of IL-37 treatment on demyelination. This could lead to the development of safer and more effective therapies for MS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis or other central nervous system autoimmune conditions.
Not a fit: Patients with autoimmune conditions not affecting the central nervous system may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage inflammation and progression of autoimmune diseases like multiple sclerosis.
How similar studies have performed: Previous research has shown promise in targeting cytokines for treating autoimmune diseases, suggesting that this approach could be effective.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Rostami, A.m. — Thomas Jefferson University
- Study coordinator: Rostami, A.m.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.